TEL AVIV, July 26- After months of sparring in a hostile takeover bid for rival Mylan NV, Teva Pharmaceutical's move to buy Allergan Plc's generic drug business instead could be a smoother ride that will bring bigger returns, faster. Israel- based Teva, the world's largest generic drugmaker, is in advanced talks to buy Allergan's generic drugs unit for between $40-...» Read More
CNBC's David Faber reports Hillshire Brands is buying Pinnacle Foods. And Faber comments on Allergan's rejection of Valeant's takeover bid.
Allergan has rejected a $47 billion takeover bid by Valeant Pharmaceuticals. The "Squawk on the Street" news team discuss m&a in pharmaceuticals and the IPO market.
Bill Ackman, Pershing Square Capital Management, explains what led him to reach out to activist investor Carl Icahn. Ackman calls him "a charming guy."
Bill Ackman, Pershing Square Capital Management, weighs in on the Valeant and Allergan controversy and long-term shareholder activism.
CNBC's Scott Wapner speaks to Bill Ackman, Pershing Square Capital Management, about the "winding down" of the old version of Fannie and Freddie and discusses the importance of reform to their programs.
AstraZeneca has rejected Pfizer's sweetened bid claiming it undervalues the company. The "Squawk on the Street" news team shares their thoughts on the latest bid and the U.S. tax code.
Pfizer CEO Ian Read recently met with U.K.-based investors to discuss a second bid for AstraZeneca, valuing the firm at $106 billion, sources said.
Alstom has until June 2 to review General Electric's $13.5 billion bid for its energy assets, reports CNBC's Mary Thompson.
Alstom is accepting GE's $13.5 billion bid for its energy assets, reports CNBC's Mary Thompson.
Jeffrey Immelt, General Electric chairman & CEO, discusses how the synergies between GE and Alstrom will likely drive earnings and increase the company's industrial mix.
CNBC's Mary Thompson reports the latest details on General Electric's attempt to acquire French company Alstom.
Nicholas Heymann, William Blair analyst, discusses General Electric's attempt to acquire Alstrom but Germany's Siemens AG is not giving up its pursuit either. Currently GE has the green light from Alstrom shareholders, says Heymann.
CNBC's David Faber reports Siemens will make an offer for Alstonm.
Jared Bernstein, senior fellow at The Center on Budget and Policy Priorities, and Rep. Todd Young, R-Ind., discusses how America's broken corporate tax code can cause companies, like Pfizer, to incorporate outside the U.S.
Discussing Pfizer's push for a $100 billion deal for AstraZeneca, with Seamus Fernandez Leerink Partners managing director.
Pfizer is working on its next move in a potential $100 billion battle for AstraZeneca after having two bids rejected. CNBC's Meg Tirrell reports buying AstraZeneca would boost Pfizer's cancer drug pipeline.
The "Squawk on the Street" team weigh in on Pfizer's bid to takeover European drug maker AstraZeneca.
CNBC's Dominic Chu provides a timeline of Bill Ackman's stake in Allergan.
Activist investor Carl Icahn comments on Bill Ackman's role in the Valeant Pharmaceuticals bid for Allergan. The "Squawk on the Street" team provide insight.
The "Squawk on the Street" news team discuss the involvement of Bill Ackman in the deal between Valeant Pharmaceuticals and Allergan.